Skip to main content

Ra Capital Management, L.P.

13F filer · CIK 0001346824
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$11.5BU.S. long equity reported on 13F
Positions8416 new · 17 closed
Net flow last quarter+$678MBuys minus sells
Top 10 positions weight60.4%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202684 positions
ASNDAscendis Pharma A/S$2.74B23.83%16.59%Not reportedQ1 2015
PBLSParabilis Medicines, Inc.$792M6.88%23.73%NewQ2 2026
RYTMRhythm Pharmaceuticals, Inc.$740M6.43%9.69%Not reportedQ2 2018
PCVXVaxcyte, Inc.$667M5.80%7.93%Not reportedQ2 2020
SIONSionna Therapeutics, Inc.$436M3.79%21.93%Not reportedQ1 2025
TYRATyra Biosciences, Inc.$390M3.39%20.45%Not reportedQ3 2021
EWTXEdgewise Therapeutics, Inc.$341M2.96%7.79%-19.5%Q1 2021
NAMSNewAmsterdam Pharma Co N.V.$324M2.81%8.12%Not reportedQ4 2022
COAGHemab Therapeutics Holdings, Inc.$287M2.49%16.72%NewQ2 2026
SEPNSepterna, Inc.$234M2.04%15.32%Not reportedQ4 2024
BCAXBicara Therapeutics Inc.$215M1.87%11.01%Not reportedQ3 2024
MLYSMineralys Therapeutics, Inc.$208M1.80%8.71%Not reportedQ1 2023
GHRSGH Research PLC$205M1.78%12.31%-0.5%Q2 2021
IRONDisc Medicine, Inc.$179M1.56%6.39%Not reportedQ1 2025
SGPSpyGlass Pharma, Inc.$179M1.55%23.98%Not reportedQ1 2026
ARTVArtiva Biotherapeutics, Inc.$174M1.51%72.65%+82.2%Q3 2024
JANXJanux Therapeutics, Inc.$172M1.49%18.32%Not reportedQ2 2021
TSHATaysha Gene Therapies, Inc.$160M1.39%7.24%Not reportedQ3 2023
BCRXBiocryst Pharmaceuticals Inc$158M1.38%6.20%Not reportedQ3 2013
WVEWave Life Sciences, Inc.$157M1.36%13.96%Not reportedQ4 2015
NUVLNuvalent, Inc.$154M1.34%39.83%-50.8%Q2 2024
ABVXAbivax S.A.$151M1.31%1.44%NewQ2 2026
ORKAOruka Therapeutics, Inc.$148M1.29%2.55%NewQ2 2026
CLYMClimb Bio, Inc.$147M1.28%19.68%Not reportedQ3 2021
SLDBSolid Biosciences Inc.$120M1.04%11.45%+28.9%Q1 2018
ZLABZai Lab Ltd$109M0.95%0.51%+0.6%Q4 2024
SPRYARS Pharmaceuticals, Inc.$87M0.76%10.92%Not reportedQ4 2020
XNCRXencor Inc$84.9M0.74%7.10%+7.7%Q4 2013
JBIOJade Biosciences, Inc.$81.6M0.71%5.78%Not reportedQ2 2025
NTLAIntellia Therapeutics, Inc.$76.6M0.67%3.23%Not reportedQ2 2021
LBRXLB Pharmaceuticals Inc$71.7M0.62%7.70%Not reportedQ3 2025
DFTXDefinium Therapeutics, Inc.$70.6M0.61%1.12%NewQ2 2026
ACRSAclaris Therapeutics, Inc.$67.3M0.58%9.10%+87.0%Q4 2015
FDMT4D Molecular Therapeutics, Inc.$67.2M0.58%9.15%Not reportedQ2 2023
SANASana Biotechnology, Inc.$65.4M0.57%6.26%NewQ2 2026
DMRADamora Therapeutics, Inc.$62.4M0.54%3.89%0.0%Q1 2026
MNPRMonopar Therapeutics$61.8M0.54%9.94%Not reportedQ4 2024
ABOSAcumen Pharmaceuticals, Inc.$56.1M0.49%29.03%Not reportedQ3 2021
GERNGeron Corp$54.8M0.48%6.67%-32.9%Q2 2020
RZLTRezolute, Inc.$49.1M0.43%9.81%+2.9%Q4 2025
EVMNEvommune, Inc.$46.4M0.40%9.63%Not reportedQ4 2025
VORVor Biopharma Inc.$44.2M0.38%4.41%-55.6%Q1 2021
IPSCCentury Therapeutics, Inc.$43.5M0.38%9.83%Not reportedQ2 2021
AKTSAktis Oncology, Inc.$42.4M0.37%2.46%-12.6%Q1 2026
BIOABioAge Labs, Inc.$41M0.36%3.65%+1.3%Q3 2024
CCCCC4 Therapeutics, Inc.$37.4M0.32%6.51%Not reportedQ4 2020
MIRMMirum Pharmaceuticals, Inc.$37.3M0.32%0.49%Not reportedQ1 2026
CAPRCapricor Therapeutics, Inc.$36.3M0.32%2.59%Not reportedQ4 2025
PEPGPepGen Inc.$36.1M0.31%29.01%Not reportedQ2 2022
PRLDPrelude Therapeutics Inc$34.5M0.30%8.13%NewQ2 2026
Q1 2026Reported May 15, 202685 positions
ASNDAscendis Pharma A/S$2.35B24.92%16.59%Not reportedQ1 2015
PCVXVaxcyte, Inc.$667M7.07%7.95%+7.0%Q2 2020
RYTMRhythm Pharmaceuticals, Inc.$580M6.14%9.74%Not reportedQ2 2018
TYRATyra Biosciences, Inc.$467M4.95%20.51%Not reportedQ3 2021
SIONSionna Therapeutics, Inc.$397M4.21%21.97%Not reportedQ1 2025
EWTXEdgewise Therapeutics, Inc.$328M3.48%9.70%Not reportedQ1 2021
NAMSNewAmsterdam Pharma Co N.V.$306M3.24%8.19%Not reportedQ4 2022
NUVLNuvalent, Inc.$260M2.75%80.98%+34.8%Q2 2024
DNTHDianthus Therapeutics, Inc.$219M2.32%4.78%+62.1%Q1 2024
MLYSMineralys Therapeutics, Inc.$208M2.21%9.33%+5.0%Q1 2023
SGPSpyGlass Pharma, Inc.$208M2.20%23.99%NewQ1 2026
WVEWave Life Sciences, Inc.$196M2.07%14.03%+48.2%Q4 2015
SEPNSepterna, Inc.$168M1.78%15.58%Not reportedQ4 2024
IRONDisc Medicine, Inc.$157M1.66%6.42%+24.0%Q1 2025
JANXJanux Therapeutics, Inc.$156M1.65%18.38%Not reportedQ2 2021
BCRXBiocryst Pharmaceuticals Inc$151M1.60%6.23%Not reportedQ3 2013
BCAXBicara Therapeutics Inc.$144M1.53%11.07%+4.3%Q3 2024
PRAXPraxis Precision Medicines, Inc.$120M1.28%1.34%Not reportedQ1 2024
GHRSGH Research PLC$108M1.14%12.38%Not reportedQ2 2021
ZLABZai Lab Ltd$107M1.14%0.51%Not reportedQ4 2024
TSHATaysha Gene Therapies, Inc.$105M1.12%8.20%Not reportedQ3 2023
VORVor Biopharma Inc.$96.4M1.02%9.98%Not reportedQ1 2021
GERNGeron Corp$95M1.01%9.96%Not reportedQ2 2020
SPRYARS Pharmaceuticals, Inc.$87.2M0.92%10.94%Not reportedQ4 2020
SRPTSarepta Therapeutics, Inc.$84.9M0.90%3.70%NewQ1 2026
SYRESpyre Therapeutics, Inc.$81.8M0.87%2.06%Not reportedQ4 2025
EVMNEvommune, Inc.$80.3M0.85%9.70%+1.0%Q4 2025
CLYMClimb Bio, Inc.$77.4M0.82%23.66%+0.1%Q3 2021
SLDBSolid Biosciences Inc.$67.2M0.71%9.49%+60.7%Q1 2018
ARTVArtiva Biotherapeutics, Inc.$63.5M0.67%39.87%Not reportedQ3 2024
DMRADamora Therapeutics, Inc.$62.1M0.66%3.98%NewQ1 2026
XNCRXencor Inc$59.1M0.63%6.61%Not reportedQ4 2013
LBRXLB Pharmaceuticals Inc$54.5M0.58%7.70%Not reportedQ3 2025
JBIOJade Biosciences, Inc.$51.6M0.55%7.44%Not reportedQ2 2025
ABOSAcumen Pharmaceuticals, Inc.$49.5M0.52%29.06%+40.6%Q3 2021
FDMT4D Molecular Therapeutics, Inc.$47M0.50%9.66%-10.7%Q2 2023
FULCFulcrum Therapeutics, Inc.$46.4M0.49%9.09%Not reportedQ3 2022
CAPRCapricor Therapeutics, Inc.$45.8M0.49%2.61%Not reportedQ4 2025
IPSCCentury Therapeutics, Inc.$40.1M0.43%9.86%Not reportedQ2 2021
OLMAOlema Pharmaceuticals, Inc.$38.8M0.41%2.98%Not reportedQ4 2020
LENZLENZ Therapeutics, Inc.$38.2M0.41%13.33%Not reportedQ1 2024
MNPRMonopar Therapeutics$36.6M0.39%9.96%Not reportedQ4 2024
PEPGPepGen Inc.$35.5M0.38%29.03%Not reportedQ2 2022
DSGNDesign Therapeutics, Inc.$31.6M0.34%4.76%+103.4%Q1 2021
MIRMMirum Pharmaceuticals, Inc.$29.4M0.31%0.52%NewQ1 2026
BIOABioAge Labs, Inc.$28.9M0.31%3.72%Not reportedQ3 2024
LXEOLexeo Therapeutics, Inc.$28.7M0.30%6.75%Not reportedQ1 2024
ASMBAssembly Biosciences, Inc.$28.3M0.30%6.42%Not reportedQ3 2025
RZLTRezolute, Inc.$28M0.30%9.53%Not reportedQ4 2025
AKTSAktis Oncology, Inc.$26.9M0.28%2.81%NewQ1 2026
Q4 2025Reported Feb 17, 202671 positions
ASNDAscendis Pharma A/S$2.19B22.46%16.59%Not reportedQ1 2015
CDTXCidara Therapeutics, Inc.$743M7.62%10.70%Not reportedQ2 2015
RYTMRhythm Pharmaceuticals, Inc.$714M7.31%9.92%+17.4%Q2 2018
RNAMAvidity Biosciences, Inc.$623M6.39%5.71%Not reportedQ3 2021
PCVXVaxcyte, Inc.$495M5.07%8.18%-10.4%Q2 2020
SIONSionna Therapeutics, Inc.$407M4.17%22.15%-5.2%Q1 2025
NAMSNewAmsterdam Pharma Co N.V.$335M3.43%8.35%-5.8%Q4 2022
TYRATyra Biosciences, Inc.$321M3.29%22.71%Not reportedQ3 2021
WVEWave Life Sciences, Inc.$309M3.17%9.70%0.0%Q4 2015
MLYSMineralys Therapeutics, Inc.$266M2.72%8.98%Not reportedQ1 2023
EWTXEdgewise Therapeutics, Inc.$259M2.65%9.82%Not reportedQ1 2021
SEPNSepterna, Inc.$195M2.00%15.61%Not reportedQ4 2024
NUVLNuvalent, Inc.$189M1.94%60.08%+50.8%Q2 2024
IRONDisc Medicine, Inc.$157M1.61%5.22%+25.3%Q1 2025
JANXJanux Therapeutics, Inc.$154M1.58%18.53%Not reportedQ2 2021
PEPGPepGen Inc.$131M1.34%29.13%Not reportedQ2 2022
TSHATaysha Gene Therapies, Inc.$130M1.33%8.26%Not reportedQ3 2023
SPRYARS Pharmaceuticals, Inc.$127M1.30%10.94%Not reportedQ4 2020
BCRXBiocryst Pharmaceuticals Inc$123M1.26%7.43%Not reportedQ3 2013
BCAXBicara Therapeutics Inc.$117M1.20%12.29%Not reportedQ3 2024
PRAXPraxis Precision Medicines, Inc.$110M1.13%1.48%Not reportedQ1 2024
GHRSGH Research PLC$97.5M1.00%12.38%Not reportedQ2 2021
GERNGeron Corp$84.2M0.86%9.97%+5.6%Q2 2020
ACLXArcellx, Inc.$82.6M0.85%2.19%-58.3%Q2 2024
CLYMClimb Bio, Inc.$77.7M0.80%23.64%-64.1%Q3 2021
VORVor Biopharma Inc.$70.7M0.72%13.96%+172.7%Q1 2021
BLTEBelite Bio, Inc$69.2M0.71%1.10%-50.6%Q3 2025
FULCFulcrum Therapeutics, Inc.$68.5M0.70%9.09%-40.8%Q3 2022
LENZLENZ Therapeutics, Inc.$66.9M0.68%13.33%Not reportedQ1 2024
DNTHDianthus Therapeutics, Inc.$66.4M0.68%3.73%-43.8%Q1 2024
OLMAOlema Pharmaceuticals, Inc.$65M0.67%3.20%Not reportedQ4 2020
EVMNEvommune, Inc.$59.2M0.61%10.97%NewQ4 2025
JBIOJade Biosciences, Inc.$56.6M0.58%7.44%+245.6%Q2 2025
SYRESpyre Therapeutics, Inc.$53.1M0.54%2.07%NewQ4 2025
LXEOLexeo Therapeutics, Inc.$49.7M0.51%6.85%Not reportedQ1 2024
LBRXLB Pharmaceuticals Inc$49.2M0.50%8.73%+24.3%Q3 2025
MNPRMonopar Therapeutics$43.6M0.45%9.97%+30.5%Q4 2024
CAPRCapricor Therapeutics, Inc.$43.5M0.45%2.63%NewQ4 2025
FDMT4D Molecular Therapeutics, Inc.$42.4M0.43%9.81%+23.9%Q2 2023
IVVDInvivyd, Inc.$42.3M0.43%6.07%Not reportedQ3 2021
ARTVArtiva Biotherapeutics, Inc.$42.3M0.43%40.14%Not reportedQ3 2024
GRALGRAIL, Inc.$36.7M0.38%1.06%NewQ4 2025
ASMBAssembly Biosciences, Inc.$34.7M0.36%6.44%Not reportedQ3 2025
SLDBSolid Biosciences Inc.$32.8M0.34%7.36%Not reportedQ1 2018
ABOSAcumen Pharmaceuticals, Inc.$31.5M0.32%24.65%Not reportedQ3 2021
BNTCBenitec Biopharma Inc.$24.9M0.26%5.40%Not reportedQ3 2015
CTNMContineum Therapeutics, Inc.$24.9M0.26%9.44%+2.7%Q3 2025
RZLTRezolute, Inc.$21.7M0.22%9.61%NewQ4 2025
ACRVAcrivon Therapeutics, Inc.$20.1M0.21%26.35%Not reportedQ4 2022
NKTXNkarta, Inc.$20M0.20%15.20%Not reportedQ3 2020
Q3 2025Reported Nov 14, 202567 positions
ASNDAscendis Pharma A/S$2.04B25.19%16.94%Not reportedQ1 2015
RYTMRhythm Pharmaceuticals, Inc.$574M7.07%8.52%+2.2%Q2 2018
PCVXVaxcyte, Inc.$431M5.31%9.20%Not reportedQ2 2020
RNAMAvidity Biosciences, Inc.$376M4.64%5.89%+18.9%Q3 2021
CDTXCidara Therapeutics, Inc.$322M3.97%11.47%Not reportedQ2 2015
SIONSionna Therapeutics, Inc.$307M3.79%23.49%Not reportedQ1 2025
ETNB89bio, Inc.$292M3.60%13.41%Not reportedQ4 2019
NAMSNewAmsterdam Pharma Co N.V.$288M3.55%8.96%Not reportedQ4 2022
MLYSMineralys Therapeutics, Inc.$278M3.42%9.27%+19.1%Q1 2023
JANXJanux Therapeutics, Inc.$273M3.37%18.61%Not reportedQ2 2021
ACLXArcellx, Inc.$249M3.07%5.26%Not reportedQ2 2024
LENZLENZ Therapeutics, Inc.$195M2.40%14.62%Not reportedQ1 2024
TYRATyra Biosciences, Inc.$171M2.10%22.88%Not reportedQ3 2021
EWTXEdgewise Therapeutics, Inc.$169M2.08%9.86%+5.3%Q1 2021
WVEWave Life Sciences, Inc.$133M1.64%11.36%Not reportedQ4 2015
SEPNSepterna, Inc.$132M1.62%15.67%Not reportedQ4 2024
DNTHDianthus Therapeutics, Inc.$113M1.39%6.69%Not reportedQ1 2024
BCAXBicara Therapeutics Inc.$110M1.35%12.74%Not reportedQ3 2024
GHRSGH Research PLC$110M1.35%14.75%Not reportedQ2 2021
SPRYARS Pharmaceuticals, Inc.$109M1.34%10.99%Not reportedQ4 2020
NUVLNuvalent, Inc.$108M1.33%39.83%Not reportedQ2 2024
IRONDisc Medicine, Inc.$104M1.28%4.51%Not reportedQ1 2025
VORVor Biopharma Inc.$96.6M1.19%21.96%0.0%Q1 2021
FULCFulcrum Therapeutics, Inc.$94.1M1.16%18.90%Not reportedQ3 2022
PEPGPepGen Inc.$92.7M1.14%61.17%+87.7%Q2 2022
GERNGeron Corp$82.7M1.02%9.46%Not reportedQ2 2020
TSHATaysha Gene Therapies, Inc.$77M0.95%8.60%Not reportedQ3 2023
BLTEBelite Bio, Inc$64.8M0.80%2.75%NewQ3 2025
CLYMClimb Bio, Inc.$63.2M0.78%46.08%Not reportedQ3 2021
SRRKScholar Rock Holding Corp$43.5M0.54%1.18%+2.7%Q4 2024
GPCRStructure Therapeutics Inc.$42.5M0.52%0.83%Not reportedQ4 2023
MNPRMonopar Therapeutics$41.8M0.51%7.67%Not reportedQ4 2024
FDMT4D Molecular Therapeutics, Inc.$39.7M0.49%9.76%Not reportedQ2 2023
SLDBSolid Biosciences Inc.$35.9M0.44%7.46%0.0%Q1 2018
MTSRMetsera, Inc.$35.4M0.44%0.64%Not reportedQ1 2025
ARTVArtiva Biotherapeutics, Inc.$28.3M0.35%40.34%Not reportedQ3 2024
LBRXLB Pharmaceuticals Inc$28.1M0.35%7.02%NewQ3 2025
TVTXTravere Therapeutics, Inc.$27.5M0.34%1.29%Not reportedQ4 2020
ASMBAssembly Biosciences, Inc.$26.1M0.32%6.45%NewQ3 2025
ABOSAcumen Pharmaceuticals, Inc.$25.5M0.31%24.65%Not reportedQ3 2021
CTNMContineum Therapeutics, Inc.$24.9M0.31%7.57%NewQ3 2025
NKTXNkarta, Inc.$22.4M0.28%15.21%Not reportedQ3 2020
LRMRLarimar Therapeutics, Inc.$19.5M0.24%7.06%Not reportedQ2 2020
IVVDInvivyd, Inc.$18.8M0.23%7.98%Not reportedQ3 2021
TNGXTango Therapeutics, Inc.$16.8M0.21%1.79%Not reportedQ3 2021
PRMEPrime Medicine, Inc.$16.6M0.20%1.66%NewQ3 2025
RCUSArcus Biosciences, Inc.$15.5M0.19%1.06%Not reportedQ1 2025
ACRVAcrivon Therapeutics, Inc.$15.1M0.19%26.44%Not reportedQ4 2022
HOWLWerewolf Therapeutics, Inc.$13.2M0.16%14.13%Not reportedQ2 2021
QUREuniQure N.V.$11.7M0.14%0.32%Not reportedQ1 2020
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.